Drug Names
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Amgen's Lumakras, Vectibix Net FDA Approval in KRAS G12C-Mutant Colorectal Cancer
The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.
Pfizer's Breast Cancer Drug Ibrance on CMS List for Next Round of IRA Price Negotiations
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
HHS Calls Vertex's Case for Fertility Program a 'Distraction,' Urges Court to Rule in Its Favor
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run afoul of anti-kickback laws.
Jan 15, 2025
Jan 15, 2025
Dec 11, 2024